Passa al contenuto
Merck
  • Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation.

Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation.

The Journal of cell biology (2018-03-15)
Zhe Sha, Helena M Schnell, Kerstin Ruoff, Alfred Goldberg
ABSTRACT

Proteasome inhibitors are used as research tools and to treat multiple myeloma, and proteasome activity is diminished in several neurodegenerative diseases. We therefore studied how cells compensate for proteasome inhibition. In 4 h, proteasome inhibitor treatment caused dramatic and selective induction of GABARAPL1 (but not other autophagy genes) and p62, which binds ubiquitinated proteins and GABARAPL1 on autophagosomes. Knockdown of p62 or GABARAPL1 reduced cell survival upon proteasome inhibition. p62 induction requires the transcription factor nuclear factor (erythroid-derived 2)-like 1 (Nrf1), which simultaneously induces proteasome genes. After 20-h exposure to proteasome inhibitors, cells activated autophagy and expression of most autophagy genes by an Nrf1-independent mechanism. Although p62 facilitates the association of ubiquitinated proteins with autophagosomes, its knockdown in neuroblastoma cells blocked the buildup of ubiquitin conjugates in perinuclear aggresomes and of sumoylated proteins in nuclear inclusions but did not reduce the degradation of ubiquitinated proteins. Thus, upon proteasome inhibition, cells rapidly induce p62 expression, which enhances survival primarily by sequestering ubiquitinated proteins in inclusions.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Tapsigargina, ≥98% (HPLC), solid film
Sigma-Aldrich
Monoclonal Anti-GAPDH, clone GAPDH-71.1, purified from hybridoma cell culture
Sigma-Aldrich
DL-Sulforaphane, ≥90% (HPLC), synthetic, liquid
Sigma-Aldrich
Monoclonal Anti-ATF4 antibody produced in mouse, clone 2B3, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
MISSION® esiRNA, targeting human TFEB
Sigma-Aldrich
MISSION® esiRNA, targeting human KLF4
Sigma-Aldrich
MISSION® esiRNA, targeting human NFE2